Steinbach, et al., “Effects of GC4419 (avasopasem manganese) on chronic kidney disease in head and neck cancer patients treated with radiation and cisplatin.” J Clin Oncol 2020;38(suppl; abstr 12071); doi: 10.1200/JCO.2020.38.15_suppl.12071, ACSO, May 29, 2020.
Holmlund, et al. “ROMAN: Reduction in oral mucositis with avasopasem manganese (GC4419)–phase III trial in patients receiving chemoradiotherapy for locally advanced, nonmetastatic head and neck cancer.” J Clin Oncol 2020;38(suppl; abstr TPS6596); doi: 10.1200/JCO.2020.38.15_suppl.TPS6596, ACSO, May 29, 2020.
Moser, et al. “Adaptive dose optimization trial of stereotactic body radiation therapy (SBRT) with or without GC4419 (avasopasem manganese) in pancreatic cancer.” J Clin Oncol 2020;38(suppl; abstr TPS4670); doi: 10.1200/JCO.2020.38.15_suppl.TPS4670, ACSO, May 29, 2020.
C. M. Anderson, C. M. Lee, D. Saunders, et al., “Tumor Outcomes of Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer.” Multidisciplinary Head and Neck Cancer symposium, Scottsdale, Arizona, February 27-29, 2020.
Carryn M. Anderson, Christopher M. Lee, Deborah P. Saunders, Amarinthia Curtis, Neal Dunlap, Chaitali Nangia, Arielle S. Lee, Sharon M. Gordon, Philip Kovoor, Roberto Arevalo-Araujo, Voichita Bar-Ad, Abhinand Peddada, Kyle Colvett, Douglas Miller, Anshu K. Jain, James Wheeler, Dukagjin Blakaj, Marcelo Bonomi, Sanjiv S. Agarwala, Madhur Garg, Francis Worden, Jon Holmlund, Jeffrey M. Brill, Matt Downs, Stephen T. Sonis, Sanford Katz, and John M. Buatti
Journal of Clinical Oncology 2019 37:34, 3256-3265
Brock, et al., “The radioprotector GC4419 ameliorates radiation induced lung fibrosis while enhancing the response of non-small cell lung cancer tumors to high dose per fraction radiation exposures.” ASTRO 2018, Henry B. Gonzalez Convention Center, San Antonio, Texas, October 21 – 24, 2018.